SEROCONVERSION SURVEILLANCE PROJECT

血清转化监测项目

• 批准号: 3811118
• 负责人: WILLIAM FRICKE
• 金额: --
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3811118
• 关键词: AIDS /HIV test; HIV infections; antiviral antibody; blood preservation; blood transfusion; hemophilia As; human immunodeficiency virus 1; human subject; immunologic assay /test; serology /serodiagnosis

The Seroconversion Surveillance Project has completed 3 1\2 years of data gathering on the incidence of HIV antibody conversion in hemophiliacs. Data on 7214 patients treated at 125 Hemophilia Treatment Centers has been gathered and analyzed. Thirty patients were identified that seroconverted during this time period, and eight of them met the CDC criteria for seroconversion on clotting factor concentrates that had been treated to eliminate/inactivate contaminating viruses. None of the eight had been treated exclusively with concentrates that were made from HIV antibody tested plasma and had been treated to kill infectious viruses. At this time we conclude that the risk of HIV infection from currently available concentrates that are made from HIV antibody screened plasma is extremely low. An abstract was presented at the 1990 AIDS meeting in San Francisco and a manuscript is in preparation.

血清转化监测项目已经完成了3年半的数据 收集关于血友病患者艾滋病毒抗体转换发生率的资料。 在125家血友病治疗中心接受治疗的7214例患者的数据已经 收集和分析。 确定了30名血清转化的患者， 在此期间，其中8人符合CDC标准， 凝血因子浓缩物的血清转化， 消除/消除污染病毒。 八个人中没有一个 专门用HIV抗体制成的浓缩物治疗 测试血浆，并已处理杀死传染性病毒。 在这个 我们得出结论，目前可用的艾滋病毒感染风险 由HIV抗体筛选血浆制成的浓缩物非常 低 1990年在旧金山弗朗西斯科举行的艾滋病会议上， 手稿正在准备中